This site is intended for healthcare professionals only


Use of beta-blocker is associated with lower mortality in patients with coronary artery disease with or without COPD

Safoura Sheikh Rezaei, Christoph Rinner, Paulina Ratajczak, et al.
Clin Respir J 2018
doi: 10.1111/crj.12968

Beta-blockers are recommended in the treatment of coronary artery disease (CAD) due to their efficacy in reducing disease-related morbidity and mortality. However, in patients with a co-diagnosis of chronic obstructive pulmonary disease (COPD), beta-blockers are less frequently prescribed due to concerns over their effect on patient lung function and fear of acute bronchospasms. Despite these fears, emerging evidence has shown that cardio-selective beta-blockers may have a beneficial effect in the treatment of patients with CAD and COPD. But there is little evidence available of the use of beta-blockers and their clinical impact in patients with CAD and COPD in Austria. The aim of this study was to investigate the epidemiological data on beta-blocker use in hospitalised CAD patients in Austria between 2006 and 2007. Using this data, researchers explored the association in beta-blocker use and overall mortality in patients with CAD and a co-diagnosis of COPD. Results demonstrated that of the 65,717 patients diagnosed with CAD, 46% were also diagnosed with COPD. Of this 46%, 77% were recorded users of beta-blockers. Analysis highlighted that 6.9% of these beta-blocker users diagnosed with COPD died within 6 months compared with 22.6% of non-users. In comparison, in patients diagnosed with CAD only, 5.4% of beta-blocker users and 23.1% of non-users died within 6 months. Researchers concluded that mortality of beta-blocker users was markedly lower than that of non-users in patients with or without COPD. Based on these findings, they recommended the use of these therapies in patients with CAD and a co-diagnosis of COPD to help improve patient outcomes.

Other summaries

Media partners

Developed in partnership with

Funded by

Media partners:

The Primary Care Respiratory Academy has been developed and is produced by Cogora, the publisher of Pulse, Nursing in Practice, Healthcare Leader, Management in Practice and The Pharmacist working in partnership with PCRS.

All educational content for the website and videos has been initiated and produced by PCRS and Cogora.

The Primary Care Respiratory Academy is sponsored by Chiesi Ltd.